Anthracycline conjugates having a novel linker and methods for their production
CA 2016584 C · Owner: Bristol-Myers Company · Inventors: Braslawsky, Gary R.; Kiener, Peter A.; Kaneko, Takushi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to novel conjugates methods for their production, pharmaceutical compositions and methods for delivering cytotoxic anthracyclines to a selected population of cells desired to be eliminated. More particularly, the invention relates to anthracycline conjugates comprising at least one anthracycline molecule linked to a molecule that is reactive with a cell population to be eliminated. According to one embodiment of the invention, the conjugate is comprised of an antibody reactive with a selected cell population, the antibody having a number of anthracycline molecules linked to its structure. Each anthracycline molecule, having a keto group at the C-13 position, is …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 11, 1990 and granted June 29, 1999. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 11, 2010.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 11, 2012.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.